Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Current Deferred Revenue: 2024

Historic Current Deferred Revenue for Day One Biopharmaceuticals (DAWN) over the last 1 years, with Dec 2024 value amounting to $1.6 million.

  • Day One Biopharmaceuticals' Current Deferred Revenue rose 58.48% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 58.48%. This contributed to the annual value of $1.6 million for FY2024, which is N/A change from last year.
  • Day One Biopharmaceuticals' Current Deferred Revenue amounted to $1.6 million in FY2024.
  • In the past 5 years, Day One Biopharmaceuticals' Current Deferred Revenue ranged from a high of $1.6 million in FY2024 and a low of $1.6 million during FY2024.
  • Its 1-year average for Current Deferred Revenue is $1.6 million, with a median of $1.6 million in 2024.